Luye Pharma Group Dividends and Buybacks
Dividend criteria checks 0/6
Luye Pharma Group does not currently pay a dividend.
Key information
0%
Dividend yield
0%
Buyback Yield
| Total Shareholder Yield | 0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | HK$0.123 |
| Payout ratio | 0% |
Recent dividend and buyback updates
No updates
Recent updates
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Dec 22
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares
Sep 25Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?
Aug 29Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors
Jun 19We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed
May 21Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Apr 26Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?
Feb 29Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S
Jan 09Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Dec 19A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)
Nov 24Is Luye Pharma Group (HKG:2186) A Risky Investment?
Sep 12Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price
Aug 17Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
May 10We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt
Sep 20Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if 2186's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2186's dividend payments have been increasing.
Dividend Yield vs Market
| Luye Pharma Group Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (2186) | 0% |
| Market Bottom 25% (HK) | 3.3% |
| Market Top 25% (HK) | 8.0% |
| Industry Average (Pharmaceuticals) | 4.0% |
| Analyst forecast (2186) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate 2186's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2186's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: 2186 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2186 has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 16:56 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Luye Pharma Group Ltd. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Jessica Li | BofA Global Research |
| Lok Kwan Chiu | CCB International Securities Limited |